JP6352251B2 - Ｃｒｍ１９７担体タンパク質に結合したｈｉｖｇｐ４１ペプチドを含む免疫原性化合物 - Google Patents

Ｃｒｍ１９７担体タンパク質に結合したｈｉｖｇｐ４１ペプチドを含む免疫原性化合物 Download PDF

Info

Publication number
JP6352251B2
JP6352251B2 JP2015514666A JP2015514666A JP6352251B2 JP 6352251 B2 JP6352251 B2 JP 6352251B2 JP 2015514666 A JP2015514666 A JP 2015514666A JP 2015514666 A JP2015514666 A JP 2015514666A JP 6352251 B2 JP6352251 B2 JP 6352251B2
Authority
JP
Japan
Prior art keywords
peptide
formula
crm197
composition
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015514666A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015519359A5 (enExample
JP2015519359A (ja
Inventor
クルゼ，ジョエル
ホ・ツォン・ファン，ラファエル
デフォンテーヌ，ドミニク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INNAVIRVAX
Original Assignee
INNAVIRVAX
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INNAVIRVAX filed Critical INNAVIRVAX
Publication of JP2015519359A publication Critical patent/JP2015519359A/ja
Publication of JP2015519359A5 publication Critical patent/JP2015519359A5/ja
Application granted granted Critical
Publication of JP6352251B2 publication Critical patent/JP6352251B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2015514666A 2012-05-31 2013-05-30 Ｃｒｍ１９７担体タンパク質に結合したｈｉｖｇｐ４１ペプチドを含む免疫原性化合物 Active JP6352251B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305602.0A EP2668959B1 (en) 2012-05-31 2012-05-31 Immunogenic compounds comprising HIV gp41 peptide coupled to CRM197 carrier protein
EP12305602.0 2012-05-31
PCT/IB2013/054482 WO2013179262A1 (en) 2012-05-31 2013-05-30 Immunogenic compounds comprising hiv gp41 peptide coupled to crm197 carrier protein

Publications (3)

Publication Number Publication Date
JP2015519359A JP2015519359A (ja) 2015-07-09
JP2015519359A5 JP2015519359A5 (enExample) 2016-06-23
JP6352251B2 true JP6352251B2 (ja) 2018-07-04

Family

ID=48793339

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015514666A Active JP6352251B2 (ja) 2012-05-31 2013-05-30 Ｃｒｍ１９７担体タンパク質に結合したｈｉｖｇｐ４１ペプチドを含む免疫原性化合物

Country Status (21)

Country Link
US (1) US9511136B2 (enExample)
EP (2) EP2668959B1 (enExample)
JP (1) JP6352251B2 (enExample)
KR (1) KR102077876B1 (enExample)
CN (1) CN104507496B (enExample)
AU (1) AU2013269120B2 (enExample)
BR (1) BR112014029861B1 (enExample)
CA (1) CA2875162C (enExample)
DK (1) DK2668959T3 (enExample)
EA (1) EA027803B1 (enExample)
ES (2) ES2528109T3 (enExample)
HR (1) HRP20150058T1 (enExample)
IN (1) IN2014DN10128A (enExample)
MX (1) MX360206B (enExample)
PL (1) PL2668959T3 (enExample)
PT (1) PT2668959E (enExample)
RS (1) RS53769B1 (enExample)
SI (1) SI2668959T1 (enExample)
UA (1) UA118542C2 (enExample)
WO (1) WO2013179262A1 (enExample)
ZA (1) ZA201409023B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140335119A1 (en) * 2004-02-06 2014-11-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) POLYPEPTIDE DERIVED FROM gp41, A VACCINE COMPOSITION COMPRISING SAID POLYPEPTIDE, AND USES FOR TREATING AN INFECTION BY AN HIV VIRUS IN AN INDIVIDUAL
RS63080B1 (sr) * 2015-04-17 2022-04-29 Biolife Science Qld Ltd Kompozicija vakcine i njene upotrebe
WO2016184973A1 (en) * 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016184962A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
EP3574915A1 (en) * 2018-05-29 2019-12-04 Neovacs Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
EP4115900A1 (en) * 2021-07-05 2023-01-11 Diaccurate Novel antigens and vaccines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1445614A1 (en) * 2003-02-06 2004-08-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) A method for the in vitro assessment of the progression status of an HIV virus in an invidual
AR047062A1 (es) * 2003-12-17 2006-01-04 Wyeth Corp Conjugados portadores de peptidos inmunogenicos a beta y metodos para producirlos
US20110305749A1 (en) * 2008-08-28 2011-12-15 Mogens Ryttergaard Duch HIV-1 Envelope Polypeptides for HIV Vaccine
US7965010B2 (en) * 2008-09-03 2011-06-21 Bose Corporation Linear motor with patterned magnet arrays
WO2010040853A1 (en) * 2008-10-10 2010-04-15 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for the screening of candidate substances active against the infection of a subject by a hiv virus and kits for performing the said method

Also Published As

Publication number Publication date
PL2668959T3 (pl) 2015-04-30
UA118542C2 (uk) 2019-02-11
HRP20150058T1 (hr) 2015-04-10
CA2875162A1 (en) 2013-12-05
EP2854846B1 (en) 2018-09-12
MX360206B (es) 2018-10-24
MX2014014526A (es) 2015-06-02
CA2875162C (en) 2021-09-14
US20150147348A1 (en) 2015-05-28
EA027803B1 (ru) 2017-09-29
JP2015519359A (ja) 2015-07-09
DK2668959T3 (en) 2015-01-26
BR112014029861A2 (pt) 2017-07-25
EP2854846A1 (en) 2015-04-08
WO2013179262A1 (en) 2013-12-05
CN104507496A (zh) 2015-04-08
ZA201409023B (en) 2016-08-31
AU2013269120B2 (en) 2017-04-20
SI2668959T1 (sl) 2015-03-31
EP2668959B1 (en) 2014-11-05
KR20150032266A (ko) 2015-03-25
ES2528109T3 (es) 2015-02-04
EP2668959A1 (en) 2013-12-04
IN2014DN10128A (enExample) 2015-08-21
CN104507496B (zh) 2018-08-03
US9511136B2 (en) 2016-12-06
PT2668959E (pt) 2015-02-05
ES2701084T3 (es) 2019-02-20
BR112014029861B1 (pt) 2022-05-24
RS53769B1 (sr) 2015-06-30
KR102077876B1 (ko) 2020-02-14
EA201491969A1 (ru) 2015-04-30
AU2013269120A1 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
TWI379839B (en) Aβ immunogenic peptide carrier conjugates and methods of producing same
JP6352251B2 (ja) Ｃｒｍ１９７担体タンパク質に結合したｈｉｖｇｐ４１ペプチドを含む免疫原性化合物
TWI355390B (en) Immunogenic peptide carrier conjugates and methods
CA2793087C (en) Peptides, conjugates and method for increasing immunogenicity of a vaccine
US10596238B2 (en) Methods and compositions related to immunogenic fibrils
US20090123488A1 (en) Compositions and methods for the treatment and prophylaxis of Alzheimer's disease
US20250381144A1 (en) Tabletization of peptide self-assemblies and methods of making and using the same
CN116472055A (zh) 治疗阿尔兹海默氏病的多表位疫苗
JP2023541671A (ja) シヌクレイノパチーの処置のためのアルファ－シヌクレインワクチン
JPH05506234A (ja) ワクチン組成物
CN105377876A (zh) 免疫原性肽缀合物及以之诱导抗流感治疗性抗体应答的方法
WO2018085488A1 (en) Universal mammalian influenza vaccine
JP2010500407A (ja) Ｈｉｖ−１の複数の株及びサブタイプを治療及び予防するための組成物及び方法
US11793873B2 (en) Bivalent dengue/hepatitis B vaccines
JP2001505763A (ja) Ｈｉｖ ｐ―１７ペプチドフラグメント、それを含有する組成物並びにその製造及び使用方法
JP2003533542A (ja) Ｔ細胞結合リガンド、それを含むペプチド構築物およびそれらの免疫障害を処置するための使用

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170703

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180417

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180508

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180606

R150 Certificate of patent or registration of utility model

Ref document number: 6352251

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250